tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

cardiovascular disease

0

Caitlin Rothermel

Posted on March 7, 2013 by Patti Peeples, R.Ph., Ph.D.

What do you think?  Should PROs be included in composite endpoints along with more traditional clinical measures?  Read Cardiovascular Disease and Patient-reported Outcomes – Can Composite Endpoints Work? by Caitlin Rothermel and weigh in!

Guest Bloggers cardiovascular disease, clinical trials, composite endpoints, Evidence-based medicine, PROs

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • Podcast Q&A: The Benefits of Linking SDOH with Other Real-World Data
  • How Quality Research Initiatives are Advancing Precision Oncology and Value-Based Care
  • Podcast Q&A: Improving the Representativeness of Research
  • Podcast Q&A: Literature Reviews and Global Value Dossiers

HealthEconomics.Com Twitter Feed

www_healthecon Follow

@ ·
now

Reply on Twitter Retweet on Twitter Like on Twitter Twitter
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes